MultiOmic Health

MultiOmic Health is a London-based AI-enabled drug discovery company focused on metabolic syndrome-related diseases — a cluster of chronic conditions including type 2 diabetes, chronic kidney disease, atherosclerotic cardiovascular disease, and non-alcoholic fatty liver disease. Collectively these conditions account for an estimated $2 trillion in global healthcare costs annually, yet current treatments only delay progression rather than address underlying molecular causes. MultiOmic was founded in 2021 to change this by bringing the precision medicine revolution — already transforming oncology — to the far larger and underserved metabolic syndrome space.

The company's proprietary MOHSAIC® platform integrates multi-omics patient data (genomic, proteomic, metabolomic, and more), AI-driven computational systems biology modelling, and targeted wet laboratory experiments to identify distinct patient subpopulations and discover novel precision therapeutic concepts. MultiOmic partners with healthcare providers, biobanks, and research institutions to source de-identified patient data, building a deep longitudinal data lake that powers its discovery engine.

MultiOmic Health has raised over $8.7 million in seed funding across two rounds, with its most recent $6.2 million seed extension led by Hoxton Ventures with participation from Ada Ventures, MMC Ventures, and Verve Ventures. The company's initial platform focus is chronic kidney disease in diabetic patients, a condition accounting for an estimated $300 billion in annual global healthcare costs. MultiOmic commercialises its discoveries through partnerships with established biopharma companies.